【佳學(xué)基因檢測(cè)】細(xì)胞外囊泡在膠質(zhì)母細(xì)胞瘤發(fā)病機(jī)制中的新作用

腫瘤基因檢測(cè)十大公司排序

閱讀腫瘤基因解碼協(xié)會(huì)如何提升基因檢測(cè)的正確性知悉《Metab Brain Dis》在.?2022 Sep 9.發(fā)表了一篇題目為《細(xì)胞外囊泡在膠質(zhì)母細(xì)胞瘤發(fā)病機(jī)制中的新作用》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由Maryam Khayamzadeh,?Vahid Niazi,?Bashdar Mahmud Hussen,?Mohammad Taheri,?Soudeh Ghafouri-Fard,?Mohammad Samadian?等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究?jī)?nèi)容關(guān)鍵詞：

生物標(biāo)志物,表達(dá),細(xì)胞外囊泡,膠質(zhì)母細(xì)胞瘤,小RNA

腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果

雖然腦腫瘤并不十分常見(jiàn)，但由于缺乏適當(dāng)?shù)闹委熀桶l(fā)現(xiàn)較晚，它們會(huì)導(dǎo)致高死亡率。膠質(zhì)母細(xì)胞瘤是賊常見(jiàn)的原發(fā)性腦腫瘤類型。這種惡性腫瘤具有高度侵襲性的行為。已發(fā)現(xiàn)不同類型轉(zhuǎn)錄物的表達(dá)譜、許多基因組基因座的甲基化狀態(tài)和染色體畸變會(huì)影響膠質(zhì)母細(xì)胞瘤的病程以及反復(fù)和轉(zhuǎn)移的傾向。賊近的研究表明，膠質(zhì)母細(xì)胞瘤細(xì)胞產(chǎn)生細(xì)胞外囊泡，其貨物可以影響鄰近細(xì)胞的行為。幾種 miRNA，例如 miR-301a、miR-221、miR-21、miR-16、miR-19b、miR-20、miR-26a、miR-92、miR-93、miR-29a、miR-222、miR-已顯示 221 和 miR-30a 被膠質(zhì)母細(xì)胞瘤來(lái)源的細(xì)胞外囊泡轉(zhuǎn)移并增強(qiáng)這些細(xì)胞的惡性行為。膠質(zhì)母細(xì)胞瘤衍生的細(xì)胞外囊泡的其他成分是 EGFRvIII mRNA/蛋白、Ndfip1、PTEN、MYC ssDNA 和 IDH1 mRNA。在當(dāng)前的綜述中，我們討論了關(guān)于膠質(zhì)母細(xì)胞瘤來(lái)源的細(xì)胞外囊泡的分子組成及其對(duì)這種惡性腫瘤的進(jìn)展及其對(duì)治療方式的耐藥性的影響的現(xiàn)有數(shù)據(jù)。表達(dá);細(xì)胞外囊泡；膠質(zhì)母細(xì)胞瘤；小RNA。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國(guó)際數(shù)據(jù)庫(kù)描述：

While brain tumors are not extremely frequent, they cause high mortality due to lack of appropriate treatment and late detection. Glioblastoma is the most frequent type of primary brain tumor. This malignant tumor has a highly aggressive behavior. Expression profile of different types of transcripts, methylation status of a number of genomic loci and chromosomal aberrations have been found to affect course of glioblastoma and propensity for recurrence and metastasis. Recent studies have shown that glioblastoma cells produce extracellular vesicles whose cargo can affect behavior of neighboring cells. Several miRNAs such as miR-301a, miR-221, miR-21, miR-16, miR-19b, miR-20, miR-26a, miR-92, miR-93, miR-29a, miR-222, miR-221 and miR-30a have been shown to be transferred by glioblastoma-derived extracellular vesicles and enhance the malignant behavior of these cells. Other components of glioblastoma-derived extracellular vesicles are EGFRvIII mRNA/protein, Ndfip1, PTEN, MYC ssDNA and IDH1 mRNA. In the current review, we discuss the available data about the molecular composition of glioblastoma-derived extracellular vesicles and their impact on the progression of this malignant tumor and its resistance to therapeutic modalities.Keywords:?Biomarker; Expression; Extracellular vesicle; Glioblastoma; miRNA.